EMD Serono acquires two PostEra AI-designed fertility drug programmes

EMD Serono, Inc., the United States and Canadian Healthcare business of Merck KGaA, Darmstadt, Germany, has acquired two fertility drug programmes developed by artificial intelligence-focused biotechnology company PostEra. The transaction covers small-molecule agonists targeting the follicle-stimulating hormone receptor, or FSHR, for ovarian stimulation in in vitro fertilization and agonists targeting the luteinizing hormone/choriogonadotropin receptor, or LHCGR, for potential use in male infertility and as an ovulation trigger in IVF. EMD Serono will take sole responsibility for further development and potential worldwide commercialization of the programmes, while financial terms were not disclosed.

PostEra developed the candidates over approximately two years using its Proton AI platform, which applies computational methods to small-molecule drug discovery and medicinal chemistry. The commercial proposition is unusually clear: fertility treatment remains heavily dependent on injected hormones, and successful oral small molecules acting on the same receptor pathways could potentially simplify treatment for patients. That opportunity remains preclinical, however, meaning EMD Serono is acquiring scientific programmes rather than medicines with demonstrated human efficacy.

Why would oral FSHR and LHCGR drugs represent more than a convenience improvement in fertility treatment?

Controlled ovarian stimulation used in IVF commonly relies on injectable gonadotropins that patients administer repeatedly over a treatment cycle. Oral drugs capable of reproducing the required receptor activity could reduce injection burden, simplify storage and administration, and potentially alter how fertility clinics manage treatment protocols. The appeal therefore extends beyond convenience because a more straightforward delivery format could influence adherence, patient experience and possibly treatment access.

PostEra’s FSHR programme is designed to stimulate the same receptor pathway activated by follicle-stimulating hormone, while the LHCGR programme targets the receptor involved in luteinizing hormone and human chorionic gonadotropin signaling. Creating orally bioavailable small molecules capable of producing sufficiently controlled receptor activation has historically been technically difficult, which is why injectable biologic hormones remain central to fertility treatment.

Preclinical receptor activity alone does not establish that oral therapy will provide the precision required in IVF. Ovarian stimulation involves careful dose adjustment and monitoring because insufficient stimulation can reduce egg yield while excessive stimulation can increase safety risks. The clinical value of PostEra’s programmes will therefore depend on pharmacokinetics, controllability, dose response and safety as much as on the convenience of swallowing a tablet.

Why does the acquisition fit Merck KGaA’s existing fertility franchise rather than create an entirely new business?

Merck KGaA already has a substantial commercial position in fertility and endocrinology. The franchise generated €494 million of second-quarter 2026 sales and €957 million during the first half, with Gonal-f contributing €339 million and Pergoveris generating €186 million in the first six months. Fertility and Endocrinology represented approximately 23% of Healthcare sales during the period, giving Merck an established customer base and commercial infrastructure for reproductive medicine.

That installed commercial position could reduce the market-development risk associated with the PostEra assets if they progress successfully. EMD Serono already interacts with fertility specialists, clinics and treatment centers that use injectable products, allowing future oral candidates to be developed within a franchise where the company understands treatment pathways and purchasing behaviour. The acquisition therefore appears more like a potential format and pipeline evolution inside an existing business than diversification into an unfamiliar therapeutic market.

The strategic challenge is that oral alternatives could eventually compete with parts of Merck KGaA’s own injectable portfolio. That cannibalization risk can also be defensive, because a company already exposed to fertility biologics may prefer to control a disruptive oral technology rather than allow a competitor to redefine treatment administration. Whether that logic becomes economically relevant will depend on the candidates advancing far enough to enter human trials.

What does PostEra gain by transferring the programmes before clinical development?

Developing reproductive-endocrinology drugs through clinical testing requires specialized trial design, regulatory expertise and significant capital. PostEra can transfer those downstream obligations to a pharmaceutical company with existing fertility infrastructure while potentially retaining economic exposure through the undisclosed transaction terms. Because financial details were not announced, it is not possible to determine whether PostEra received upfront cash, milestones, royalties or another structure.

The transaction nevertheless provides external validation for Proton. Artificial intelligence drug-discovery companies frequently point to molecule-generation speed or laboratory results, but pharmaceutical acquisitions offer a different signal because a buyer must commit resources to further development. EMD Serono’s decision does not prove the programmes will succeed clinically, but it shows that a specialist fertility business considered them sufficiently promising to assume development responsibility.

PostEra can also redeploy internal resources toward other programmes rather than funding two fertility assets through increasingly expensive stages. That model is common among platform biotechnology companies seeking to balance proprietary development with asset monetization. The resulting economics are attractive only if transaction proceeds and retained rights compensate adequately for surrendering future ownership.

How material is the acquisition for Merck KGaA’s current financial profile?

Merck KGaA reported second-quarter 2026 group sales of €5.4 billion and EBITDA pre of €1.6 billion, with both measures growing organically. Healthcare sales reached €2.2 billion, although organic Healthcare revenue declined 3.4% as portfolio gains from acquired rare-disease products offset weakness elsewhere. The PostEra transaction is therefore unlikely to be financially material in the near term unless undisclosed payments are unusually large.

The more relevant issue is pipeline renewal. Fertility and Endocrinology first-half sales declined from €1.016 billion in 2025 to €957 million in 2026, while Gonal-f revenue fell to €339 million from €392 million. Pergoveris grew, but the overall franchise does not currently have the same growth profile as Merck KGaA’s newer rare-disease assets.

Merck KGaA shares closed around €132.70 on Xetra on September 9, down from €137.85 on September 3, a decline of roughly 3.7% across that interval. The PostEra announcement alone is too small and too early-stage to explain the share movement, particularly because investors are simultaneously assessing broader group earnings, acquisitions and pipeline events.

The acquisition becomes strategically important only if one or both programmes advance from computationally designed molecules into clinically validated fertility treatments. Human pharmacology capable of delivering controllable ovarian stimulation or ovulation triggering through an oral regimen would give Merck KGaA an opportunity to modernize a franchise already generating close to €2 billion annually on the basis of its first-half run rate. Failure in early human testing would leave the acquisition as a useful technology experiment but not a meaningful commercial change.

Key takeaways on EMD Serono’s acquisition of PostEra fertility programmes

• EMD Serono has acquired two fertility programmes developed by PostEra.
• The transaction covers small-molecule FSHR and LHCGR agonist programmes.
• PostEra developed the candidates using its Proton artificial intelligence platform.
• The FSHR programme is aimed at ovarian stimulation in IVF.
• The LHCGR programme could potentially be used for male infertility and ovulation triggering.
• EMD Serono will control further development and potential worldwide commercialization.
• Financial terms were not disclosed.
• Merck KGaA’s Fertility and Endocrinology franchise generated €957 million in first-half 2026 sales.
• The programmes remain preclinical and have not yet established safety or efficacy in humans.
• Clinical controllability and oral pharmacokinetics will determine whether the programmes can challenge injected fertility treatments.